Autor: "Colombel, Jean-Frédéric" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Risk Factors for Developing Inflammatory Bowel Disease Within and Across Families with a Family History of IBD.
Autorzy:: Torres J; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.; Division of Gastroenterology, Hospital da Luz, Lisboa, Portugal.; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gomes C; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.
Jensen CB; Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Agrawal M; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
Ribeiro-Mourão F; Pediatrics Department, Centro Materno Infantil do Norte - Centro Hospitalar e Universitário do Porto, Porto, Portugal.; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
Jess T; Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.; Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.
Colombel JF; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Allin KH; Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
Burisch J; Gastrounit, Medical Division, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.; Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen, Denmark.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2023 Jan 27; Vol. 17 (1), pp. 30-36.
Typ publikacji:: Journal Article
MeSH Terms:: Spondylitis, Ankylosing*/drug therapy
Inflammatory Bowel Diseases*/epidemiology
Inflammatory Bowel Diseases*/genetics
Inflammatory Bowel Diseases*/drug therapy
Colitis, Ulcerative*/epidemiology
Colitis, Ulcerative*/genetics
Colitis, Ulcerative*/drug therapy
Humans ; Female ; Risk Factors ; Anti-Bacterial Agents/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Prediction and Prevention of Inflammatory Bowel Disease.
Autorzy:: Torres J; Division of Gastroenterology, Hospital Beatriz Ângelo, Loures, Portugal.; Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Halfvarson J; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Rodríguez-Lago I; Department of Gastroenterology, Hospital de Galdakao, and Biocruces Bizkaia Health Research Institute, Bilbao, Spain.
Hedin CRH; Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden.; Karolinska University Hospital, Gastroenterology unit, Department of Gastroenterology, Dermatovenereology and Rheumatology, Stockholm, Sweden.
Jess T; Department of Epidemiology Research, Statens Serum Institut, Copenhagen S, Denmark.; PREDICT, Institute of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Dubinsky M; Division of Pediatric Gastroenterology and Nutrition, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, Icahn School of Medicine Mount Sinai, New York, NY, USA.
Croitoru K; Center for Inflammatory Bowel Disease, Mount Sinai Hospital, Toronto, ON, Canada.; Division of Gastroenterology and Hepatology, University of Toronto, Toronto, ON, Canada.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Sep 25; Vol. 15 (9), pp. 1443-1454.
Typ publikacji:: Journal Article
MeSH Terms:: Precision Medicine*
Inflammatory Bowel Diseases/*etiology
Inflammatory Bowel Diseases/*prevention & control
Humans ; Inflammatory Bowel Diseases/diagnosis ; Predictive Value of Tests ; Risk Factors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.
Autorzy:: Wellens J; Translational Gastro-Intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK.; Translational Research for Gastrointestinal Diseases, University Hospitals Leuven, Leuven, Belgium.
Colombel JF; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Satsangi JJ; Translational Gastro-Intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK.
Wong SY; Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2021 Aug 02; Vol. 15 (8), pp. 1376-1386.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Vaccination*/methods
COVID-19/*prevention & control
COVID-19 Vaccines/*immunology
Immunosuppressive Agents/*immunology
Inflammatory Bowel Diseases/*drug therapy
Humans ; Immunity, Cellular ; Immunity, Humoral ; Immunosuppressive Agents/therapeutic use ; SARS-CoV-2

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.
Autorzy:: Colombel JF; Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
D'haens G; Amsterdam University Medical Centers - Inflammatory Bowel Disease Unit, University of Amsterdam, Amsterdam, The Netherlands.
Lee WJ; Global Gastroenterology, AbbVie, North Chicago, IL, USA.
Petersson J; Global Gastroenterology, AbbVie, North Chicago, IL, USA.
Panaccione R; Inflammatory Bowel Disease Clinic, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Feb 10; Vol. 14 (2), pp. 254-266.
Typ publikacji:: Journal Article; Systematic Review
MeSH Terms:: Patient Care Planning*
Inflammatory Bowel Diseases/*therapy
Humans ; Remission Induction ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Autorzy:: Hanauer SB; Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Sandborn WJ; University of California San Diego, La Jolla, CA USA.
Feagan BG; Robarts Clinical Trials, Western University, London, ON, Canada.
Gasink C; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Jacobstein D; Janssen Research & Development, LLC, Spring House, PA, USA.
Zou B; Janssen Research & Development, LLC, Spring House, PA, USA.
Johanns J; Janssen Research & Development, LLC, Spring House, PA, USA.
Adedokun OJ; Janssen Research & Development, LLC, Spring House, PA, USA.
Sands BE; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rutgeerts P; University Hospital, Gasthuisberg, Leuven, Belgium.
de Villiers WJS; Stellenbosch University, Stellenbosch, South Africa.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ghosh S; NIHR Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2020 Jan 01; Vol. 14 (1), pp. 23-32.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Crohn Disease/*drug therapy
Ustekinumab/*therapeutic use
Double-Blind Method ; Drug Administration Schedule ; Humans ; Injections, Subcutaneous ; Maintenance Chemotherapy ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data.
Autorzy:: Philip G; Global Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA.
Cornillie F; Global Medical Affairs, MSD International, Kriens-Luzern, Switzerland.
Adedokun JO; Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.
Melsheimer R; Medical Affairs, Janssen Biologics BV, Leiden, The Netherlands.
Rutgeerts P; Department of Endoscopy, University Hospital Gasthuisberg, Leuven, Belgium.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Marano C; Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 27; Vol. 13 (10), pp. 1257-1264.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal/*administration & dosage
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*administration & dosage
Antibodies, Monoclonal/blood ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/therapeutic use ; C-Reactive Protein/analysis ; Feces/chemistry ; Gastrointestinal Agents/blood ; Gastrointestinal Agents/pharmacology ; Gastrointestinal Agents/therapeutic use ; Humans ; Leukocyte L1 Antigen Complex/analysis ; Remission Induction/methods ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy.
Autorzy:: Panés J; Department of Gastroenterology, Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Lindsay JO; Department of Gastrointestinal and Liver Services, Royal London Hospital, Barts Health NHS Trust, London, UK.
Teich N; Innere Medizin/Gastroenterologie, Internistische Gemeinschaftspraxis, Leipzig, Germany.
Lindgren S; Department of Gastroenterology, Lund University, Malmo, Sweden.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Cornillie F; Global Medical Affairs, MSD International, Kriens-Luzern, Switzerland.
Flynn HA; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Huyck S; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Stryszak P; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Yao R; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Philip G; MRL, Merck & Co., Inc., Kenilworth, NJ, USA.
Reinisch W; Klinische Abt. Gastroenterologie & Hepatologie, Universitätsklinik für Innere Medizin III, Vienna, Austria.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2019 Sep 19; Vol. 13 (9), pp. 1148-1157.
Typ publikacji:: Comparative Study; Journal Article; Observational Study
MeSH Terms:: Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Infliximab/*therapeutic use
Adrenal Cortex Hormones/therapeutic use ; Adult ; Europe ; Female ; Gastrointestinal Agents/adverse effects ; Humans ; Immunosuppressive Agents/therapeutic use ; Infections/chemically induced ; Infliximab/adverse effects ; Male ; Product Surveillance, Postmarketing ; Prospective Studies ; Registries

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis.
Autorzy:: Sandborn WJ; University of California San Diego, San Diego, CA, USA.; UC San Diego Health System, San Diego, CA, USA.
Colombel JF; Mount Sinai Hospital, New York, NY, USA.
Panaccione R; University of Calgary, Calgary, AB, Canada.
Dulai PS; University of California San Diego, San Diego, CA, USA.
Rosario M; Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Cao C; Takeda Pharmaceuticals USA Inc., Deerfield, IL, USA.
Barocas M; Takeda Pharmaceuticals USA Inc., Deerfield, IL, USA.
Lasch K; Takeda Pharmaceuticals USA Inc., Deerfield, IL, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2019 Feb 01; Vol. 13 (2), pp. 172-181.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Antibodies, Monoclonal, Humanized/*therapeutic use
Colitis, Ulcerative/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adolescent ; Adult ; Aged ; Colitis, Ulcerative/pathology ; Female ; Humans ; Male ; Middle Aged ; Remission Induction/methods ; Severity of Illness Index ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials.
Autorzy:: Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Byrne SO; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Khalid JM; Takeda International - UK Branch, London, UK.
Kempf C; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Geransar P; Takeda Pharmaceuticals International AG, Zurich, Switzerland.
Bhayat F; Takeda Pharmaceuticals International Co., Cambridge, MA, USA.
Rubin DT; University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2019 Jan 01; Vol. 13 (1), pp. 50-57.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:: Adrenal Cortex Hormones/*administration & dosage
Antibodies, Monoclonal, Humanized/*therapeutic use
Arthralgia/*epidemiology
Arthritis/*epidemiology
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Disease Progression ; Humans ; Incidence

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Autorzy:: Rosario M; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
French JL; Metrum Research Group LLC, Tariffville, CT, USA.
Dirks NL; Metrum Research Group LLC, Tariffville, CT, USA.
Sankoh S; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Parikh A; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Yang H; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
Danese S; Inflammatory Bowel Disease Clinical and Research Unit, Istituto Clinico Humanitas, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Smyth M; Takeda Development Centre Europe Ltd, London, UK.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and Department of Internal Medicine, McMaster University, Hamilton, ON, Canada.
Sands BE; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Sans M; Digestive Diseases Service, Centro Médico Teknon, Barcelona, Spain.
Fox I; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.; Pokaż więcej
Źródło:: Journal of Crohn's & colitis [J Crohns Colitis] 2018 Mar 28; Vol. 12 (4), pp. 510.
Typ publikacji:: Journal Article; Published Erratum

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Colombel, Jean-Frédéric"" wg kryterium: Autor

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Język